Myriad data.
Individual care.


Data-backed drug development

How do you fast-track the development of novel treatments and therapies? How do you provide deeper, more effective care?

By developing technology-powered health services that elevate clinical care and deliver deeper clinical insights. By learning from every patient. By testing and validating novel treatments in the real world. In real time. By collecting and systematising live, dynamic, multidimensional patient data and clinical evidence. By making patients part of the clinical research journey and clinical innovation part of every patient’s health journey. Welcome to Emyria and evidence-generating care.

We Are

Caring. Curious. Courageous.



We're developing new care models for patients with unmet needs by using novel treatments and by bringing together patients, clinicians, researchers and medical innovators.

To dive deeper into each patient’s case, especially patients who have run out of options. To deliver a greater depth of clinical care. To think more deeply and innovatively about helping people thrive and live happier, healthier lives.


We’re accelerating drug development by pioneering new ways to collect, standardise and analyse dynamic patient data and clinical evidence.

To discover insights previously hidden from view. To test, validate and develop novel treatments and therapies. In the real world. In collaboration with our clinicians, patients and clinical evidence specialists.


A world-class clinical service for patients with unmet needs

A bespoke data platform gathering ethically-sourced clinical evidence with patients

Deep data analysis to reveal unique IP and targeted drug-response insights

Data-backed drug development towards formal registration



Registered treatments for patients with unmet needs.

Emyria treatments and drug development programs are focussed on addressing unmet needs. Emyria's programs are unique in that they are informed by the carefully generated Real World Evidence (RWE) we create with our patients across our clinical service. Our clinical-trial-grade data provides deep dose-response information that helps us understand what treatments work, in whom and when. We use those insights to develop our own treatments and support formal registration with major global regulators.
EMD-003 | a cannabinoid medicine targeting mental health
EMD-004 | a cannabinoid medicine targeting irritable bowel syndrome (IBS)
Additional registration programs underway with strategic partners


Robust and ethically-sourced real-world patient data providing unique treatment insights.

Our unique data platform helps us manage, monitor and improve the safety and efficacy of novel treatments for patients with unmet medical needs. We generate patient data and Real World Evidence (RWE) while providing care. Our data is a source of unique insights and intellectual property and also helps us improve care.
More than 2.6M data points, and growing!
Multiple drug developers using our data
75% of FDA approvals incorporate real-world evidence and growing


Improving care for patients with unmet needs.

Across our clinical network, our clinician-led care teams provide personalised, evidence-generating care for patients with unmet needs. We monitor and evaluate promising new treatments, in the real world, while generating unique insights that help us provide individualised care. We treat more than 44 different debilitating and costly health concerns, including mental health, chronic pain, addiction, neurodegenerative, gastrointestinal and musculoskeletal conditions. The evidence we collect in our clinic is regulator-grade, Real-World Evidence (RWE) which informs our care and powers our own drug development programs.
Emerald Clinics (Australia) | Sapphire Medical (UK partner)
Over 40 unmet needs
Patients aged 2-96
More than 3,000 patients under care, and growing.


Remote care, powered by your smartphone and backed by a clinical team.

Our TGA-registered, clinician-led, remote screening, triage and monitoring platforms help track symptoms, clinical signs and other risk factors away from our clinics. We apply this technology to proactively manage the health of our patients and trial participants. Our data systems ensure we obtain clinical evidence of the highest quality.
Openly: A wellness screening service, powered by your smartphone and backed by a clinical team
Actionable risk-management insights
Clinical-trial grade data capture to inform care

We see a global opportunity and believe that much of what we want to achieve today is already possible by bringing together the right talent and technology and staying caring, curious and courageous.


Ours is a collaborative vision and venture. We’re bringing people and partners together for the greater good: patients, clinicians, researchers, medical innovators and, of course, investors.

If, like us, you’re inspired by the almost limitless humanitarian and commercial potential of our evidence-generating clinical care, here’s where you can find out more about Emyria.
75 %
FDA approvals where real-world evidence (RWE) was provided, and growing.
1000 +
Unique data points collected per patient.
$ 3 T USD
Trillion USD cost of chronic disease and mental health per year in the US.
Call 1300 436 363Contact